Alumis vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alumis is a clinical-stage biopharmaceutical company developing oral TYK2 inhibitors for immune-mediated diseases including psoriasis, lupus, and inflammatory bowel disease; raised over $400M in private funding;
About
Alumis is a South San Francisco-based clinical-stage biopharmaceutical company founded in 2021 by Martin Babler and Joseph Arol, with a focus on developing precision oral therapies for patients with serious immune-mediated diseases. The company's lead program, ESK-001, is a highly selective TYK2 (tyrosine kinase 2) inhibitor targeting conditions including moderate-to-severe plaque psoriasis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. TYK2 inhibition is a validated immunology mechanism — Bristol Myers Squibb's Sotyktu (deucravacitinib) was the first approved TYK2 inhibitor — and Alumis is developing what it believes is a next-generation molecule with improved selectivity.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.